CN119137130A - Mek激酶的抑制剂 - Google Patents
Mek激酶的抑制剂 Download PDFInfo
- Publication number
- CN119137130A CN119137130A CN202380038101.5A CN202380038101A CN119137130A CN 119137130 A CN119137130 A CN 119137130A CN 202380038101 A CN202380038101 A CN 202380038101A CN 119137130 A CN119137130 A CN 119137130A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
- C07F9/5325—Aromatic phosphine oxides or thioxides (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
- C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316607P | 2022-03-04 | 2022-03-04 | |
| US63/316,607 | 2022-03-04 | ||
| PCT/US2023/063338 WO2023168203A1 (en) | 2022-03-04 | 2023-02-27 | Inhibitors of mek kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119137130A true CN119137130A (zh) | 2024-12-13 |
Family
ID=85704077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380038101.5A Pending CN119137130A (zh) | 2022-03-04 | 2023-02-27 | Mek激酶的抑制剂 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11780862B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486750A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507947A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119137130A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128622A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202342018A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023168203A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
| WO2024220427A1 (en) * | 2023-04-17 | 2024-10-24 | Kinnate Biopharma Inc. | Treatment of cancer with a mek kinase inhibitor |
| WO2025032211A1 (en) | 2023-08-09 | 2025-02-13 | Pierre Fabre Medicament | Treatment of cancer with a raf inhibitor |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ATE344791T1 (de) | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| ID30439A (id) | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| JP2002534515A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 1−複素環置換されたジアリールアミン |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| AU2482800A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| JP2003527379A (ja) | 2000-03-15 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Mex阻害物質としての5−アミド置換ジアリールアミン類 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| BR0307060A (pt) | 2002-01-23 | 2004-10-26 | Warner Lambert Co | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico |
| WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| JP4931419B2 (ja) | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| ES2444866T3 (es) | 2004-10-20 | 2014-02-27 | Merck Serono Sa | Derivados de 3-arilamino piridina |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| WO2007123939A2 (en) | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
| EP2279166A1 (en) | 2008-04-22 | 2011-02-02 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenoxybenzamides |
| AU2009279940B2 (en) | 2008-08-04 | 2014-01-16 | Merck Patent Gmbh | Novel phenylamino isonicotinamide compounds |
| WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
| CN102649773A (zh) | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途 |
| CN103570594A (zh) | 2012-08-01 | 2014-02-12 | 苏州迈泰生物技术有限公司 | 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途 |
| WO2020088390A1 (zh) * | 2018-10-29 | 2020-05-07 | 江苏先声药业有限公司 | 作为第四代egfr抑制剂的嘧啶吡唑类化合物 |
| CN113660931B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物 |
| TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
-
2023
- 2023-02-24 TW TW112107027A patent/TW202342018A/zh unknown
- 2023-02-27 EP EP23711918.5A patent/EP4486750A1/en active Pending
- 2023-02-27 WO PCT/US2023/063338 patent/WO2023168203A1/en not_active Ceased
- 2023-02-27 US US18/175,074 patent/US11780862B2/en active Active
- 2023-02-27 JP JP2024552359A patent/JP2025507947A/ja active Pending
- 2023-02-27 AR ARP230100462A patent/AR128622A1/es unknown
- 2023-02-27 CN CN202380038101.5A patent/CN119137130A/zh active Pending
- 2023-06-15 US US18/335,803 patent/US12122800B2/en active Active
-
2024
- 2024-09-19 US US18/890,248 patent/US20250250293A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486750A1 (en) | 2025-01-08 |
| US20230279033A1 (en) | 2023-09-07 |
| US11780862B2 (en) | 2023-10-10 |
| WO2023168203A1 (en) | 2023-09-07 |
| JP2025507947A (ja) | 2025-03-21 |
| US20230416286A1 (en) | 2023-12-28 |
| US20250250293A1 (en) | 2025-08-07 |
| TW202342018A (zh) | 2023-11-01 |
| US12122800B2 (en) | 2024-10-22 |
| AR128622A1 (es) | 2024-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11667634B2 (en) | Inhibitors of RAF kinases | |
| AU2018380132B2 (en) | Tubulin inhibitors | |
| US12122800B2 (en) | Inhibitors of MEK kinase | |
| JP2025540024A (ja) | TNF-α活性の調節因子 | |
| WO2022081469A1 (en) | Inhibitors of raf kinases | |
| US12595245B2 (en) | Inhibitors of MET kinase | |
| CN119384421A (zh) | 某些化学实体、组合物和方法 | |
| WO2023150681A1 (en) | Inhibitors of raf kinases | |
| US20250145599A1 (en) | Certain chemical entities, compositions, and methods | |
| KR20170048601A (ko) | 히스톤 탈메틸효소 억제제 | |
| WO2023070053A1 (en) | Inhibitors of raf kinases | |
| WO2025054260A1 (en) | Inhibitors of mek kinase | |
| CN118742542A (zh) | Met激酶的抑制剂 | |
| WO2026060099A1 (en) | Selective pi3k inhibitors | |
| WO2025032214A1 (en) | Indazole compounds and azaindazole compounds as inhibitors of raf kinases | |
| EP4727943A1 (en) | Inhibitors of met kinase | |
| HK40061750A (en) | Inhibitors of raf kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: Massachusetts, USA Applicant after: Mosaka Pharmaceutical Company Address before: Massachusetts, USA Applicant before: Mosaka Therapeutics Company Country or region before: U.S.A. |
|
| CB02 | Change of applicant information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20250728 Address after: Massachusetts, USA Applicant after: Mosaka Therapeutics Company Country or region after: U.S.A. Address before: California, USA Applicant before: Jinnaite biopharmaceutical Co. Country or region before: U.S.A. |
|
| TA01 | Transfer of patent application right |